Hormonal regulation of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 in cultured monkey Sertoli cells

被引:0
|
作者
Liu Yi-xun [1 ]
Liu Kui [1 ]
Zhou Hong-ming [1 ]
Du Qun [1 ]
Hu Zhao-yuan [1 ]
Zou Ru-jin [2 ]
机构
[1] Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, Beijing 100080, Peoples R China
[2] Kunming Inst Zool, Primate Res Ctr, Kunming 650223, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
plasminogen activator inhibitor type-1; Rhesus monkey; Sertoli cells; tissue-type plasminogen activator;
D O I
10.1093/molehr/1.1.21
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sertoli cells play a central role in the control and maintenance of spermatogenesis. Isolated Sertoli cells of mouse and rat testes have been shown to secrete plasminogen activator (PA) and a plasminogen activator inhibitor type-1 (PAI-1) in culture. In this study, we have investigated the hormonal regulation of PA and PAI-1 activities in cultured monkey Sertoli cells. Sertoli cells (5x 10(5) cells/well) isolated from infant rhesus monkey testes were preincubated at 35 degrees C for 16 h in 24-well plates precoated with poly(D-lysine) (5 mu g/cm(2)) in 0.5 ml McCoy's 5a medium containing 5% of fetal calf serum and further incubated for 48 h in 0.5 ml serum-free medium with or without various hormones or other compounds. PA as well as PAI-1 activities in the conditioned media were assayed by fibrin overlay and reverse fibrin autography techniques respectively. The Sertoli cells in vitro secreted only tissue-type PA (tPA), no detectable amount of urokinase-type PA (uPA) could be observed. Monkey Sertoli cells were also capable of secreting PAI-1. Immunocytochemical studies indicated that both tPA and PAI-1 positive staining localized in the Sertoli cells, spermatids and residual bodies of the seminiferous epithelium; Northern blot analysis further confirmed the presence of both tPA and PAI-1 mRNA in monkey Sertoli cells. Addition of follicle-stimulating hormone (FSH) or cyclic adenosine monophosphate (CAMP) derivatives or cAMP-generating agents and gonadotrophin-releasing hormone (GnRH) agonist or phorbol ester (PMA) to the cell culture significantly increased tPA activity. PAI-1 activity in the culture was also enhanced by these reagents except 8-bromo-dibutyryl-cAMP, forskolin and 3-isobutyl-1-methylxanthin (MIX) which greatly stimulated tPA activity, whereas decreased PAI-1 activity, implying that neutralization of PAI-1 activity by the high level of tPA in the conditioned media may occur. These data suggest that increased intracellular signals which activate protein kinase A (PKA), or protein kinase C (PKC) can modulate Sertoli cell tPA and PAI-1 activities. The concomitant induction of PA and PAI-1 by the same reagents in the Sertoli cells may reflect a finely tuned regulatory mechanism in which PAI-1 could limit the excession of the proteolysis.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [31] Regulation of tissue-type plasminogen activator (tPA) and type-1 plasminogen activator inhibitor (PAI-1) gene expression in rat hepatocytes in primary culture
    Uno, S
    Nakamura, M
    Ohomagari, Y
    Matsuyama, S
    Seki, T
    Ariga, T
    JOURNAL OF BIOCHEMISTRY, 1998, 123 (05): : 806 - 812
  • [32] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN NORMAL AND ENDOTOXIN-TREATED RAT AORTA
    QUAX, PHA
    PADRO, T
    EMEIS, JJ
    VANDENHOOGEN, RM
    VERHEIJEN, JH
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 834 - 834
  • [33] KINETICS OF INHIBITION OF TISSUE-TYPE AND UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 AND TYPE-2
    THORSEN, S
    PHILIPS, M
    SELMER, J
    LECANDER, I
    ASTEDT, B
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 175 (01): : 33 - 39
  • [34] TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR AND TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) LYMPHOCYTES
    ANKRI, A
    MENTZ, F
    CHEVRET, S
    COUTY, MC
    BINET, JL
    BLOOD, 1994, 84 (10) : A459 - A459
  • [35] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR IN RAYNAUD PHENOMENON
    SILVERI, F
    SERRETTI, R
    CORE, P
    BRECCIAROLI, D
    THROMBOSIS RESEARCH, 1993, 70 : S93 - S93
  • [36] Immunohistochemical localization of tissue-type plasminogen activator and type I plasminogen activator inhibitor in radicular cysts
    Tsai, CH
    Weng, SF
    Yang, LC
    Huang, FM
    Chen, YJ
    Chang, YC
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2004, 33 (03) : 156 - 161
  • [37] ON THE REVERSIBLE INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND WITH UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    LIJNEN, HR
    VANHOEF, B
    COLLEN, D
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (07) : 4041 - 4044
  • [38] THE AMOUNT OF PLASMINOGEN, TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN HUMAN THROMBI AND THE RELATION TO EX-VIVO LYSIBILITY
    VANLOON, BJP
    RIJKEN, DC
    BROMMER, EJP
    VANDERMAAS, APC
    THROMBOSIS AND HAEMOSTASIS, 1992, 67 (01) : 101 - 105
  • [39] Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
    Tsai, Shih-Jen
    ONCOTARGET, 2017, 8 (68) : 113258 - 113268
  • [40] Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study
    A.J. Simpson
    N.A. Booth
    N.R. Moore
    S.J. Lewis
    R.S. Gray
    Acta Diabetologica, 1999, 36 : 155 - 158